Brian Bressler

Dr. Brian Bressler

Clinical Associate Professor, St. Paul’s Hospital

About

Brian L Bressler, MD, MS, FRCPC

Director, Advanced IBD Training Program

Clinical Associate Professor of Medicine

St Pauls Hospital

Division of Gastroenterology, Department of Medicine, University of British Columbia

770-1190 Hornby Street

Vancouver BC

telephone 604 688 6332

fax 604 689 2004

Profile

Dr. Bressler is the Director of the Advanced IBD training program at UBC.  Dr. Bressler received his MD from the University of British Columbia and completed his residency in internal medicine and gastroenterology at the University of Toronto. He received an MS in Epidemiology from the Harvard Public School of Health and completed an advanced fellowship in IBD at Massachusetts General Hospital, Harvard Medical School.  Dr. Bressler is a recognized expert in inflammatory bowel disease.

Research Interests

His research interests include population based studies, classic clinical epidemiology studies and clinical trials in inflammatory bowel disease.

Teaching

Advanced training in Inflammatory Bowel Disease

Memberships

Canadian Medical Association

Canadian Association of Gastroenterology

Doctors of BC

BC Society of Gastroenterology

Royal College of Physicians and Surgeons

Crohns Colitis Canada

BRIGEe group

Publications

  1. Rosenfeld G, Greenup AJ, Round A, Takach O, Halparin L, Saadeddin A, Ho JK, Lee T, Enns R, Bressler B. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease.World J Gastroenterol. 2016 Sep 28;22(36):8211-8.
  2. Stanger DE, Abdulla AH, Wong FT, Alipour S, Bressler BL, Wood DA, Webb JG.
  3. Upper gastrointestinal bleeding following transcatheter aortic valve replacement: A retrospective analysis.Catheter Cardiovasc Interv. 2016 Jul 9.
  4. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results.Clin Gastroenterol Hepatol. 2016 Sep;14(9):1302-9.
  5. Shahidi N, Bressler B, Panaccione R.The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis.Therap Adv Gastroenterol. 2016 May;9(3):330-8. doi: 10.1177/1756283X16635081. Epub 2016 Mar 7. Review.
  6. Greenup AJ, Bressler B, Rosenfeld G.Medical Imaging in Small Bowel Crohn's Disease-Computer Tomography Enterography, Magnetic Resonance Enterography, and Ultrasound: "Which One Is the Best for What?".Inflamm Bowel Dis. 2016 May;22(5):1246-61.
  7. Devlin SM, Melmed GY, Irving PM, Rubin DT, Kornbluth A, Kozuch PL, Raffals LE, Velayos FS, Sparrow MP, Baidoo L, Bressler B, Cheifetz AS, Jones J, Kaplan GG, Siegel CA.Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel.Inflamm Bowel Dis. 2016 Jun;22(6):1418-24.
  8. D'Haens G, Bressler B, Danese S, Gibson P, Hanauer SB, Sandborn W.The Crohn's Disease Ulcerative Colitis Clinical Appraisal.Clin Gastroenterol Hepatol. 2016 Apr;14(4):638-9.
  9. Ou G, Rosenfeld G, Bressler B.Evaluating if colonoscopies are essential after a diverticulitis diagnosis - Author response.Can J Surg. 2016 Feb;59(1):E1-2.
  10. Carroll MW, Hamilton Z, Gill H, Simkin J, Smyth M, Espinosa V, Bressler B, Jacobson K. Pediatric Inflammatory Bowel Disease Among South Asians Living in British Columbia, Canada: A Distinct Clinical Phenotype.Inflamm Bowel Dis. 2016 Feb;22(2):387-96.
  11. Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, Leong RW, Bressler B, Ullman T, Lakatos PL, Reinisch W, Xu LA, Luo A.Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.J Crohns Colitis. 2015 Dec 30.
  12. Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group.The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. 2016 Mar;150(3):734-757.
  13. Rosenfeld G, Parker CE, MacDonald JK, Bressler B.Etrolizumab for induction of remission in ulcerative colitis.Cochrane Database Syst Rev. 2015 Dec 2;12:CD011661.
  14. Shahidi N, Bressler B, Panaccione R.Vedolizumab for the treatment of ulcerative colitis.Expert Opin Biol Ther. 2016 Jan;16(1):129-35.
  15. Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG; REACT Study Investigators.Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. 2015 Nov 7;386(10006):1825-34.
  16. Rush B, Berger L, Rosenfeld G, Bressler B.Tacrolimus Therapy for Ulcerative Colitis-Associated Post-Colectomy Enteritis.ACG Case Rep J. 2014 Oct 10;2(1):33-5.
  17. Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA.Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.Clin Gastroenterol Hepatol. 2015 Dec;13(13):2233-40.
  18. Bressler B, Panaccione R, Fedorak RN, Seidman EG.Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease.Can J Gastroenterol Hepatol. 2015 Oct;29(7):369-72.
  19. Bressler B, Bethel KP, Kleef R, Reynolds SL, Sutcliffe S, Mullins DW, Gunn H. Site-Specific Immunomodulator: A Novel Treatment for Crohn's Disease.Gastroenterol Res Pract. 2015;2015:231243.
  20. Ou G, Rosenfeld G, Brown J, Chan N, Hong T, Lim H, Bressler B. Colonoscopy after CT-diagnosed acute diverticulitis: Is it really necessary?Can J Surg. 2015 Jun 1;58(3):014514-14514.
  21. Bressler B. ACP journal club. In ulcerative colitis, current use of thiopurines was associated with nonmelanoma skin cancer.Ann Intern Med. 2015 Mar 17;162(6)
  22. Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. 2015 May;148(5):1035-1058
  23. Charlebois A, Rosenfeld G, Bressler B.The Impact of Dietary Interventions on the Symptoms of Inflammatory Bowel Disease: A Systematic Review.Crit Rev Food Sci Nutr. 2015 Jan 8:0.
  24. Lam MC, Bressler B. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies. 2014;6(9):963-71.
  25. Fu YT, Hong T, Round A, Bressler B. Impact of medical therapy on patients with Crohn's disease requiring surgical resection.World J Gastroenterol. 2014 Sep 7;20(33):11808-14.
  26. Marshall JK, Otley AR, Afif W, Bernstein CN, Hookey L, Leontiadis G, Panaccione R, Bressler B.Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease.Can J Gastroenterol Hepatol. 2014 Jul-Aug;28(7):371-2.
  27. Nguyen GC, Devlin SM, Afif W, Bressler B, Gruchy SE, Kaplan GG, Oliveira L, Plamondon S, Seow CH, Williams C, Wong K, Yan BM, Jones J.Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.Can J Gastroenterol Hepatol. 2014 May;28(5):275-85.
  28. Ou G, Kim E, Lakzadeh P, Tong J, Enns R, Ramji A, Whittaker S, Ko HH, Bressler B, Halparin L, Lam E, Amar J, Telford J. A randomized controlled trial assessing the effect of prescribed patient position changes during colonoscope withdrawal on adenoma detection.Gastrointest Endosc. 2014 Mar 11.
  29. Rosenfeld G, Fu YT, Quiney B, Qian H, Krygier D, Brown J, Vos P, Tiwari P, Telford J, Bressler B, Enns R.Does training and experience influence the accuracy of computed tomography colonography interpretation?World J Gastroenterol. 2014 Feb 14;20(6):1574-81.
  30. Bressler B, Siegel CA.Beware of the Swinging Pendulum: Anti-Tumor Necrosis Factor Mono Versus Combination Therapy for Inflammatory Bowel Disease. 2014 Feb 24.
  31. Kopylov U, Rosenfeld G, Bressler B, Seidman E.Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.Inflamm Bowel Dis. 2014 Apr;20(4):742-56.
  32. Yau AH, Ou G, Galorport C, Amar J, Bressler B, Donnellan F, Ko HH, Lam E, Enns RA.Safety and efficacy of Hemospray® in upper gastrointestinal bleeding.Can J Gastroenterol Hepatol. 2014 Feb;28(2):72-6.
  33. Nguyen GC, Bernstein CN, Bitton A, Chan AK, Griffiths AM, Leontiadis GI, Geerts W, Bressler B, Butzner JD, Carrier M, Chande N, Marshall JK, Williams C, Kearon C.Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: canadian association of gastroenterology. 2014 Mar;146(3):835-848.
  34. Lam MC, Lee T, Atkinson K, Bressler B.Time of infliximab therapy initiation and dose escalation in Crohn's disease.World J Gastroenterol. 2014 Jan 7;20(1):214-8.Brown CJ, Achkar JP, Bressler BL, Maclean AR, Remzi FH; Evidence Based Reviews in Surgery Group.Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons and the American Society of Colorectal Surgeons Evidence Based Reviews in Surgery - colorectal surgery. Dis Colon Rectum. 2014 Feb;57(2):278-81.
  35. Moore SE, McGrail KM, Peterson S, Raval MJ, Karimuddin AA, Phang PT, Bressler B, Brown CJ.Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada.Dis Colon Rectum. 2014 Jan;57(1):83-90Xia A, Stempak JM, Grist J, Bressler B, Silverberg MS, Bach H. Effect of inflammatory bowel disease therapies on immunogenicity of Mycobacterium paratuberculosis proteins.  Scand J Gastroenterol. 2013 Nov 21.
  36. Gallinger Z, Bressler B, Devlin SM, Plamondon S, Nguyen GC. A survey of perceptions and practices of complementary alternative medicine among Canadian gastroenterologists.Can J Gastroenterol. 2013 Nov 8.
  37. Brahmania M, Ou G, Bressler B, Ko HK, Lam E, Telford J, Enns R. 2 L versus 4 L of PEG3350 + electrolytes for outpatient colonic preparation: a randomized, controlled trial.Gastrointest Endosc. 2013 Oct 24.
  38. Kim E, Bressler B, Schaeffer DF, Yoshida EM. Severe cholestasis due to adalimumab in a Crohn's disease patient.World J Hepatol. 2013 Oct 27;5(10):592-5.
  39. Shahidi N, Bressler B. Effective Tuberculosis and Hepatitis Screening Prior to Anti-TNF-α Therapy: Are We There Yet?Dig Dis Sci. 2013 Oct 26.
  40. Bressler B, Devlin SM, Bernstein CN, Fedorak RN, Bitton A, Singh H, Feagan BG. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.Can J Gastroenterol. 2013 Oct;27(10):567-71.
  41. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group.Vedolizumab as induction and maintenance therapy for Crohn's disease.N Engl J Med. 2013 Aug 22;369(8):711-21.
  42. Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, Bressler B, Fedorak RN, Ghosh S, Greenberg GR, Marshall JK, Panaccione R, Seidman EG, Silverberg MS, Steinhart AH, SyR, Van Assche G, Walters TD, Sandborn WJ, Feagan BG. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.Aliment Pharmacol Ther. 2013 Sep;38(5):447-59.
  43. Rosenfeld, G, Qian H, Bressler B. The risks of post-operative complications following pre-operative infliximab therapy for Crohn’s disease in patients undergoing abdominal surgery: A systematic review and meta-analysis. J Crohns Colitis. March 2013 2 [Epub ahead of print]
  44. Etminan M, Bird ST, Delaney JA, Bressler B, Brophy JM. Isotretinoin and risk of inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol. Feb 2013;149(2):216-20.
  45. Rosenfeld G, Bressler. The truth about cigarette smoking and the risk of inflammatory bowel disease. Am J Gastroenterol. 2012 Sep;107(9):1407-8.
  46. Nguyen GC, Bressler B. A tale of two cohorts: Are we overestimating the risk of colorectal cancer in inflammatory bowel disease? Gastroenterology. 2012 Jun 20.
  47. Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B, Schreiber S, Mansfield JC, Williams M, Tang M, Visich J, Wei X, Keir M, Luca D, Danilenko D, Egen J, O'Byrne S. A randomized phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut. 2012 Jun 20.
  48. Bird ST, Liu W, Brophy JM, Bressler B, Delaney JA, Etminan M. Irritable bowel syndrome and drospirenon-containing oral contraceptives; a comparative-safety study. Curr Drug Saf. 2012 Feb 1;7(1):8-15.
  49. Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB. Abatacept for Crohn’s Disease and Ulcerative Colitis. Gastroenterology. 2012 Apr 12.
  50. Bach H, Rosenfeld G, Bressler B. Treatment of Crohn’s disease with infliximab is detrimental for the survival of Mycobacterium avium ssp. Paratuberculosis within macrophages and shows a remarkable decrease in the immunogenicity of mycobacterial proteins. J Crohns Colitis. 2012 Jun;6(5):628-9.
  51. Cheifetz AS, Melmed GY, Spiegel B, Talley J, Devlin SM, Raffals L, Irving PM, Jones J, Kaplan GG, Kozuch P, Sparrow M, Velayos F, Baidoo L, Bressler B, Siegel CA. Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survery, expert rand panel, and patient focus groups. Inflamm Bowel Dis. 2012 Feb 15
  52. Shahidi N, Fu YT, Qian H, Bressler B. Performance ofinterfreon-gamma release assays in patients with inflammatory bowel disease:A systematic review and meta-analysis. Inflamm Bowel Dis. 2012 Jan 31.
  53. Fu YT, Kim E, Bressler B. Pneumatosis intestinalis after colonscopy in a Crohn’s disease patient with mucosal healing. Inflamm Bowel Dis. 2011 Dec 6.
  54. Reid JD, Bressler, English J. A case of adalimumab-induced pneumonitis in a 45 year old man with Crohn’s disease. Can Respir J. 2011 Sep;18(5):262-4
  55. Etminan M, Delaney JA, Bressler B, Brophy JM. Oral contraceptives and the risk of gallbladder disease:a comparative safety study. CMAJ. 2011 May 17;183(8):899-904.
  56. Wong JCT, Bressler B, Salh S, Yoshida EM, Chatur N. Development of testicular germ cell cancer following successful infliximab induction therapy for ulcerative colitis. Journal of Crohn's and Colitis. 2011 April;5(2):162-164